Skip to main content

Congenica Receives $1.6M in Seed Funding

NEW YORK (GenomeWeb) – Bioinformatics firm Congenica today announced it has received £1 million ($1.6 million) from Cambridge Innovation Capital to scale up its Sapientia platform.

Sapientia is a modular and scalable data analytics tool for annotating and clinically interpreting genomic sequence data.

"Sapientia combines clinical information about the patient, information about their gene mutations, and background information about the disease phenotypes of other patients with those mutations," Matthew Hurles, co-founder of Congenica, said in a statement. "We have worked very closely with clinical geneticists to ensure that Sapientia can present this information in a way that is easy for clinicians to interpret."

The technology improves the diagnosis of rare genetic diseases, the Hinxton, UK-based firm said in a statement, and could provide future insights into the screening and treatment of rare and common diseases.

In May, the firm received £200,000 to further develop the platform.

"We see Congenica's technology as a powerful enabler that can realize the potential for a radically different type of genome analysis service," said Cambridge Innovation Capital's Robert Tansley. 

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.